China Sows Ground For TCM Market Growth With Regulatory Framework
This article was originally published in The Tan Sheet
A long-awaited law could greatly enlarge the traditional Chinese medicine market and has prompted drug makers in the country to race to develop TCM products. The potential TCM boom has multinational drug firms leaping into the fray, some to partner with locals and others establishing teams devoted to TCM R&D.
You may also be interested in...
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
Much of the biopharma and other health-related industries in China were already feeling the chill from ongoing macro-economic and other headwinds this year, which now look set to be complicated further by the added strain of social unrest over strict COVID containment policies. The combination of factors is already prompting some to take steps towards restructuring and divestments to survive.
With growing cases and deaths reported just as the country was preparing to ease some of its most restrictive COVID-19 measures, China takes new control steps amid low booster vaccine uptake and moves to halt the online sale of a repurposed domestic antiviral.